login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
ALX ONCOLOGY HOLDINGS INC (ALXO) Stock News
USA
-
Nasdaq
- NASDAQ:ALXO -
US00166B1052
-
Common Stock
1.2
USD
-0.12 (-9.09%)
Last: 12/2/2025, 8:26:22 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
ALXO Latest News, Press Relases and Analysis
All
Press Releases
14 days ago - By: FN Media Group LLC
- Mentions:
ONCY
ERAS
IMRX
PRLD
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
15 days ago - By: ALX Oncology
ALX Oncology to Present at Upcoming Investor Conferences
a month ago - By: Benzinga
Examining the Future: ALX Oncology Holdings's Earnings Outlook
4 months ago - By: Benzinga
ALX Oncology Holdings's Earnings: A Preview
15 days ago - By: ALX Oncology
ALX Oncology to Present at Upcoming Investor Conferences
26 days ago - By: ALX Oncology
ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update
26 days ago - By: ALX Oncology
ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update
a month ago - By: ALX Oncology
ALX Oncology to Report Third Quarter 2025 Financial Results and Pipeline Progress Including Evorpacept CD47 Biomarker Data to be Presented at Upcoming SITC Annual Meeting
a month ago - By: ALX Oncology
ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference
a month ago - By: ALX Oncology
ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference
2 months ago - By: ALX Oncology
ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
2 months ago - By: ALX Oncology
ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
3 months ago - By: ALX Oncology
ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer
3 months ago - By: ALX Oncology
ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer
3 months ago - By: ALX Oncology
ALX Oncology to Participate in Upcoming Investor Conferences in September
3 months ago - By: ALX Oncology
ALX Oncology to Participate in Upcoming Investor Conferences in September
4 months ago - By: ALX Oncology
ALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid Tumors
4 months ago - By: ALX Oncology
ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update
4 months ago - By: ALX Oncology
ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update
4 months ago - By: ALX Oncology
ALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025
Please enable JavaScript to continue using this application.